Since the earliest days of the pandemic, health officials have gauged the threat of COVID-19 by comparing it to the flu.
At first, it wasnt even close. People hospitalized in 2020 with the then-novel respiratory disease were five times more likely to die of their illness than were patients who had been hospitalized with influenza during the preceding flu seasons.
Immunity from vaccines and past coronavirus infections has helped tame COVID-19 to the point that when researchers compared the mortality rates of hospitalized COVID-19 and seasonal influenza patients during the height of the 2022-23 flu season, they found that the pandemic disease was only 61% more likely to result in death.
Now the same researchers have analyzed data for the the fall and winter of 2023 and 2024. Dr. Ziyad Al-Aly, director of the Clinical Epidemiology Center at the VA St. Louis Health Care System, and his colleagues expected to find that the two respiratory diseases had finally equalized.
Theres a narrative out there that the pandemic is over, that its a nothingburger, Al-Aly said. We came into this thinking we would do this rematch and find it would be like the flu from now on.
The VA team examined electronic health records of patients treated in Veterans Affairs hospitals in all 50 states between Oct. 1 and March 27. They zeroed in on patients who were admitted because they had fevers, shortness of breath or other symptoms due to either COVID-19 or influenza. (People who were admitted for another reason, such as a heart attack, and were then found to have a coronavirus infection werent included in the analysis.)
The COVID-19 patients were a little older, on average, than the flu patients (73.9 versus 70.2 years old), and they were less likely to be current or former smokers. They were also more likely to have received at least three doses of COVID-19 vaccine and less likely to have shunned the shots altogether.
Yet after Al-Aly and his colleagues accounted for these differences and a host of other factors, they found that 5.7% of the COVID-19 patients died of their disease, compared with 4.2% of the influenza patients.
In other words, the risk of death from COVID-19 was still 35% greater than it was for the flu. The findings were published Wednesday in the Journal of the American Medical Assn.
There is undeniably an impression out there that [COVID-19] is no longer a major threat to human health, Al-Aly said. I think its largely driven by opinion and an emotional itch to move beyond the pandemic, to put it all behind us. We want to believe that its like the flu, and we did until we saw the data.
Dr. Peter Chin-Hong, an infectious diseases specialist at UC San Francisco, said the study results are right in line with what he sees in his hospital.
COVID continues to make some people in our community very ill and die even in 2024, he said. Although most will not get seriously ill from COVID, for some people it is like 2020 all over again.
Thats particularly true for people who are older, who havent received their most recent recommended COVID-19 booster, and who havent taken full advantage of antivirals such as Paxlovid. Chin-Hong noted that only 5% of the COVID-19 patients in the study had been treated with antivirals before they were hospitalized.
Even if the mortality rates for the COVID-19 and flu patients had been equal, COVID-19 would still be the bigger health threat because it is sending more people to the hospital, Al-Aly said.
Between Oct. 1 and the end of March, 75.5 out of every 100,000 Americans had been hospitalized with influenza, according to the Centers for Disease Control and Prevention. During that same period, the hospitalization rate for COVID-19 was 122.9 per 100,000 Americans, the CDC says.
COVID still carries a higher risk of hospitalization, Al-Aly said. And among those hospitalized, more will die as a result.
Yet Al-Aly noted with frustration that while 48% of adults in the U.S. received a flu shot this year, only 21% of adults are up to date with their COVID-19 vaccinations, according to the CDC.
Chin-Hong added that more than 95% of adults hospitalized with COVID-19 this past fall and winter had not received the latest booster shot, according to the CDC.
Considering all the tools available to prevent hospitalizations and deaths and especially the fact that they are readily available to patients in the VA system the 35% relative risk of death from COVID-19 compared with the flu was surprisingly high, Chin-Hong said.
And its not like the flu is a trivial health threat, especially for senior citizens and people who are immunocompromised. It routinely kills tens of thousands of Americans each year, CDC data show.
Influenza is a consequential infection, Al-Aly said. Even when COVID becomes equal to the flu, its still sobering and significant.
The researchers also compared the mortality rates of VA COVID-19 patients before and after Dec. 24, when the Omicron subvariant known as JN.1 became the dominant strain in the United States. The difference was not statistically significant.
In just the last two weeks, JN.1 appears to have been overtaken by one of its descendants, a subvariant known as KP.2. Its part of a family of subvariants thats taken on the nickname FLiRT, a moniker that references some of the mutations that have cropped up on the viruses spike proteins.
So far, theres no indication that KP.2 is any more dangerous than JN.1, Al-Aly said.
Are the hospitals filling up? No, he said. Are ER rooms all over the country flooded with respiratory illness? No. Nor are there worrying changes in the amount of coronavirus detected in wastewater.
When you look at all these data streams, were not seeing ominous signs that KP.2 is something the general public should worry about, Al-Aly said.
Its also too early to tell whether KP.2 or whatever comes after it will finally erase the mortality gap between COVID-19 and the flu, he added.
Maybe when we do a rematch in 2025, that will be the case, he said.
A recenteBioMedicinestudy identifies shared immunopathology between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and melanoma differentiation-associated protein-5 (MDA5) autoimmunity.
Study:MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 pandemic (MIP-C). Image Credit: Light Studio Design / Shutterstock.com
Dermatomyositis (DM) is an autoimmune diseasethatischaracterizedby severe skin and muscle inflammation. Additionally, DM is associated with interstitial lung disease (ILD),whichcauses progressive pulmonary fibrosis.
Anti-Mi-2, which targets the Mi-2 nuclear antigen, is the first autoantibody to be associated with DM. Over time, multiple myositis-specific and related autoantibodies (MSA) havebeen identifiedfor different phenotypic patterns.
Clinically, amyopathicdermatomyositis (CADM) has been significantly associated with DM and leads to progressive ILD. CADMis expressedthrough retinoic acid-inducible gene 1 (RIG-1)-like receptor family gene, IFIH1, which encodes the MDA5 protein.
A recent study highlighted that MDA5+ cases predating the coronavirus disease 2019 (COVID-19) pandemic exhibited a significant manifestation of ILD. However, these patients did not develop the classical DM heliotropic rash and instead developed skin-based clinical symptoms, includingtender palmar papules and skin ulceration.
MDA5 is a RIG-1 helicase12 thatfunctions asan RNA sensor and pattern recognition receptor for SARS-CoV-2. A recent study revealed that variants of the IFIH1 gene confer protection against SARS-CoV-2 infections and facilitate favorable outcomes.
Thus, it isvitalto identify the factors associated with MDA5+-related disease to better understand the rise in anti-MDA5 positivity during the COVID-19 pandemic.
The current study investigated the epidemiological factors that cause MDA5+ related disease. MDA5 autoimmunity with interstitial pneumonitis cotemporaneous with the COVID-19 pandemic (MIP-C) was also investigated.
To this end, transcriptomic datasets were usedto explore the mechanismsthataresharedbetween MDA5-associated disease and COVID-19. Transcriptomic datasets were also usedto compare autoimmune lung disease, acute COVID-19 lung disease, and idiopathic pulmonary fibrosis (IPF)to better understand the origin of the MDA5+ -DM outbreak.
A modelwas developedthat connected severe anti-viral cytokine response with interferon-induced helicase C domain-containing protein 1 (IFIH1) stimulation, which is responsible for the unique immunophenotype linked with MSA-associated progressive ILD.
Data on the number ofMDA5+ cases each year between January 2018 and December 2022 was collectedfrom theLeeds Teaching Hospitals NHS Trust, which serves as an immunology laboratory reference for Yorkshire.Clinical notes for MDA5+ cases indicated patterns of symptomatic MDA5 disease, particularly the degree of ILD, treatment, therapy responses, and survival rates.
Public Health England (PHE) data allowed the researchers to quantifymonthly COVID-19 positivity ratesin Yorkshire.Data on these patients' vaccination status and severity of lung infection were also obtained.
The current study documents the features and outcomes of the surge in MDA5+ myositis or ILDthat occurredduring the COVID-19 pandemic in the United Kingdom, especially in 2021.
Six new MDA5+ cases were identified between January 2018 and December 2019, which indicates 1.2% and 0.4% MSA immunoblot positivity in the respective years. However, after the second COVID-19 wave, there was a rapid increaseinnew MDA5+ cases. More specifically, the number of new cases in 2020, 2021, and 2022 were nine, 35, and 16, respectively; therefore, therate of MDA5 positivity increased from 1.2% in 2018 to 1.7% in 2022.
Approximately 42% of MDA5+ cases were associated with progressive ILD, with about 33% exhibiting aggressive MDA5+-ILD. Both transcriptomic dataset analysis andclinical epidemiologic observations indicated that the surge in MDA5 autoimmunity and ILD during COVID-19 could be due to shared aberrant type 1-centric IFN responses but not IPF.
Considering thestudy findings and similar cases reported internationally, the current study proposed the terms MDA5-autoimmunity and MIP-C.The merit of this acronym lies in the distinct features that can separate MIP-C from the syndrome of adult MDA5+ DM57.For example, the MIP-C phenotypehas similaritiesto multisystem inflammatory syndrome in children(MIS-C), evenin somecaseswhere the patient did not have a history of COVID-19.
About 42% of new caseswere not vaccinatedbefore MDA5+ diseaseand represented milder COVID-19 infection, which could be sufficient to cause MDA5 autoimmunity.
An immune reaction or autoimmunity against MDA5 upon SARS-CoV-2and/orvaccine exposure was assessed.Thisindicated novel immunogenicity in non-immune subjects upon RNA engagement with MDA5 that increased cytokine response and induced autoimmune disease.
Theoretically, the development of herd immunity and reduced SARS-CoV-2 exposure contributed to milder symptoms in the MIP-C cohort.Taken together, MDA5 proteinactivation through natural infection orvaccination can potentially induce MIP-C.
The current transcriptomic analysis elucidated the possible causal link between the surge in anti-MDA5-positivity, COVID-19, and autoimmune ILD. In the future, these findings mustbe validatedusing multicenter cohorts across nations.
Journal reference:
State Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington Washington D.C. West Virginia Wisconsin Wyoming Puerto Rico US Virgin Islands Armed Forces Americas Armed Forces Pacific Armed Forces Europe Northern Mariana Islands Marshall Islands American Samoa Federated States of Micronesia Guam Palau Alberta, Canada British Columbia, Canada Manitoba, Canada New Brunswick, Canada Newfoundland, Canada Nova Scotia, Canada Northwest Territories, Canada Nunavut, Canada Ontario, Canada Prince Edward Island, Canada Quebec, Canada Saskatchewan, Canada Yukon Territory, Canada
Zip Code
Country United States of America US Virgin Islands United States Minor Outlying Islands Canada Mexico, United Mexican States Bahamas, Commonwealth of the Cuba, Republic of Dominican Republic Haiti, Republic of Jamaica Afghanistan Albania, People's Socialist Republic of Algeria, People's Democratic Republic of American Samoa Andorra, Principality of Angola, Republic of Anguilla Antarctica (the territory South of 60 deg S) Antigua and Barbuda Argentina, Argentine Republic Armenia Aruba Australia, Commonwealth of Austria, Republic of Azerbaijan, Republic of Bahrain, Kingdom of Bangladesh, People's Republic of Barbados Belarus Belgium, Kingdom of Belize Benin, People's Republic of Bermuda Bhutan, Kingdom of Bolivia, Republic of Bosnia and Herzegovina Botswana, Republic of Bouvet Island (Bouvetoya) Brazil, Federative Republic of British Indian Ocean Territory (Chagos Archipelago) British Virgin Islands Brunei Darussalam Bulgaria, People's Republic of Burkina Faso Burundi, Republic of Cambodia, Kingdom of Cameroon, United Republic of Cape Verde, Republic of Cayman Islands Central African Republic Chad, Republic of Chile, Republic of China, People's Republic of Christmas Island Cocos (Keeling) Islands Colombia, Republic of Comoros, Union of the Congo, Democratic Republic of Congo, People's Republic of Cook Islands Costa Rica, Republic of Cote D'Ivoire, Ivory Coast, Republic of the Cyprus, Republic of Czech Republic Denmark, Kingdom of Djibouti, Republic of Dominica, Commonwealth of Ecuador, Republic of Egypt, Arab Republic of El Salvador, Republic of Equatorial Guinea, Republic of Eritrea Estonia Ethiopia Faeroe Islands Falkland Islands (Malvinas) Fiji, Republic of the Fiji Islands Finland, Republic of France, French Republic French Guiana French Polynesia French Southern Territories Gabon, Gabonese Republic Gambia, Republic of the Georgia Germany Ghana, Republic of Gibraltar Greece, Hellenic Republic Greenland Grenada Guadaloupe Guam Guatemala, Republic of Guinea, Revolutionary People's Rep'c of Guinea-Bissau, Republic of Guyana, Republic of Heard and McDonald Islands Holy See (Vatican City State) Honduras, Republic of Hong Kong, Special Administrative Region of China Hrvatska (Croatia) Hungary, Hungarian People's Republic Iceland, Republic of India, Republic of Indonesia, Republic of Iran, Islamic Republic of Iraq, Republic of Ireland Israel, State of Italy, Italian Republic Japan Jordan, Hashemite Kingdom of Kazakhstan, Republic of Kenya, Republic of Kiribati, Republic of Korea, Democratic People's Republic of Korea, Republic of Kuwait, State of Kyrgyz Republic Lao People's Democratic Republic Latvia Lebanon, Lebanese Republic Lesotho, Kingdom of Liberia, Republic of Libyan Arab Jamahiriya Liechtenstein, Principality of Lithuania Luxembourg, Grand Duchy of Macao, Special Administrative Region of China Macedonia, the former Yugoslav Republic of Madagascar, Republic of Malawi, Republic of Malaysia Maldives, Republic of Mali, Republic of Malta, Republic of Marshall Islands Martinique Mauritania, Islamic Republic of Mauritius Mayotte Micronesia, Federated States of Moldova, Republic of Monaco, Principality of Mongolia, Mongolian People's Republic Montserrat Morocco, Kingdom of Mozambique, People's Republic of Myanmar Namibia Nauru, Republic of Nepal, Kingdom of Netherlands Antilles Netherlands, Kingdom of the New Caledonia New Zealand Nicaragua, Republic of Niger, Republic of the Nigeria, Federal Republic of Niue, Republic of Norfolk Island Northern Mariana Islands Norway, Kingdom of Oman, Sultanate of Pakistan, Islamic Republic of Palau Palestinian Territory, Occupied Panama, Republic of Papua New Guinea Paraguay, Republic of Peru, Republic of Philippines, Republic of the Pitcairn Island Poland, Polish People's Republic Portugal, Portuguese Republic Puerto Rico Qatar, State of Reunion Romania, Socialist Republic of Russian Federation Rwanda, Rwandese Republic Samoa, Independent State of San Marino, Republic of Sao Tome and Principe, Democratic Republic of Saudi Arabia, Kingdom of Senegal, Republic of Serbia and Montenegro Seychelles, Republic of Sierra Leone, Republic of Singapore, Republic of Slovakia (Slovak Republic) Slovenia Solomon Islands Somalia, Somali Republic South Africa, Republic of South Georgia and the South Sandwich Islands Spain, Spanish State Sri Lanka, Democratic Socialist Republic of St. Helena St. Kitts and Nevis St. Lucia St. Pierre and Miquelon St. Vincent and the Grenadines Sudan, Democratic Republic of the Suriname, Republic of Svalbard & Jan Mayen Islands Swaziland, Kingdom of Sweden, Kingdom of Switzerland, Swiss Confederation Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand, Kingdom of Timor-Leste, Democratic Republic of Togo, Togolese Republic Tokelau (Tokelau Islands) Tonga, Kingdom of Trinidad and Tobago, Republic of Tunisia, Republic of Turkey, Republic of Turkmenistan Turks and Caicos Islands Tuvalu Uganda, Republic of Ukraine United Arab Emirates United Kingdom of Great Britain & N. Ireland Uruguay, Eastern Republic of Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Viet Nam, Socialist Republic of Wallis and Futuna Islands Western Sahara Yemen Zambia, Republic of Zimbabwe
AstraZeneca (AZ) has shared positive results from a late-stage study evaluating the efficacy of its investigational long-acting monoclonal antibody, sipavibart, in preventing COVID-19 in immunocompromised individuals.
Despite accounting for approximately 4% of the population, immunocompromised patients make up about 25% of COVID-19 hospitalisations, intensive care unit admissions and deaths.
The phase 3 SUPERNOVA trial has been comparing sipavibart, formerly AZD3152, to tixagevimab/cilgavimab or placebo in patients aged 12 years and older who are at an increased risk of mounting an inadequate response to active immunisation and at a high risk of developing severe COVID-19.
This included solid organ transplant recipients, patients with haematologic malignancies or end-stage kidney disease, and those within one year of receiving B cell depleting therapy, with AZ noting that demographic and baseline characteristics across the treatment groups were generally well balanced.
The study met its dual primary endpoints of relative risk reduction of symptomatic COVID-19 caused by any SARS-CoV-2 variant and relative risk reduction of infections caused by SARS-CoV-2 variants not containing the F456L mutation.
Sipavibart was also shown to be well tolerated and preliminary analyses demonstrated that adverse events were balanced between the control and sipavibart arms.
By delivering infection-fighting antibodies directly to patients who often dont respond adequately to vaccines, the data supports that sipavibart has the potential to provide much-needed protection against COVID-19 in this highly vulnerable population, said SUPERNOVA trial primary investigator Ghady Haidar, University of Pittsburgh Medical Center.
AZ outlined that the data will be presented at a forthcoming medical meeting, adding that it is in dialogue with regulatory authorities on potential authorisation or approval pathways.
Iskra Reic, executive vice president, vaccines and immune therapies, AZ, said: Immunocompromised patients currently have limited or no options for COVID-19 protection and continue to face a significant burden of disease, despite often being fully vaccinated.
Sipavibart has the potential to prevent COVID-19 in the immunocompromised and we will now work with regulatory authorities globally to bring sipavibart to these vulnerable patients.
The readout comes just one week after AZ said it had begun the global withdrawal of its COVID-19 vaccine, citing a surplus of vaccines that have been updated to target new variants of the virus.
This article has been reviewed according to ScienceX's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
reputable news agency
proofread
by Karen Kaplan, Los Angeles Times
close
Since the earliest days of the pandemic, health officials have gauged the threat of COVID-19 by comparing it to the flu.
At first, it wasn't even close. People hospitalized in 2020 with the then-novel respiratory disease were five times more likely to die of their illness than were patients who had been hospitalized with influenza during the preceding flu seasons.
Immunity from vaccines and past coronavirus infections has helped tame COVID-19 to the point that when researchers compared the mortality rates of hospitalized COVID-19 and seasonal influenza patients during the height of the 202223 flu season, they found that the pandemic disease was only 61% more likely to result in death.
Now the same researchers have analyzed data for the the fall and winter of 2023 and 2024. Dr. Ziyad Al-Aly, director of the Clinical Epidemiology Center at the VA St. Louis Health Care System, and his colleagues expected to find that the two respiratory diseases had finally equalized.
"There's a narrative out there that the pandemic is over, that it's a nothingburger," Al-Aly said. "We came into this thinking we would do this rematch and find it would be like the flu from now on."
The VA team examined electronic health records of patients treated in Veterans Affairs hospitals in all 50 states between Oct. 1 and March 27. They zeroed in on patients who were admitted because they had fevers, shortness of breath or other symptoms due to either COVID-19 or influenza. (People who were admitted for another reason, such as a heart attack, and were then found to have a coronavirus infection weren't included in the analysis.)
The COVID-19 patients were a little older, on average, than the flu patients (73.9 versus 70.2 years old), and they were less likely to be current or former smokers. They were also more likely to have received at least three doses of COVID-19 vaccine and less likely to have shunned the shots altogether.
Yet after Al-Aly and his colleagues accounted for these differences and a host of other factors, they found that 5.7% of the COVID-19 patients died of their disease, compared with 4.2% of the influenza patients.
In other words, the risk of death from COVID-19 was still 35% greater than it was for the flu. The findings were published Wednesday in the Journal of the American Medical Association.
"There is undeniably an impression out there that (COVID-19) is no longer a major threat to human health," Al-Aly said. "I think it's largely driven by opinion and an emotional itch to move beyond the pandemic, to put it all behind us. We want to believe that it's like the flu, and we diduntil we saw the data."
Dr. Peter Chin-Hong, an infectious diseases specialist at UC San Francisco, said the study results are right in line with what he sees in his hospital.
"COVID continues to make some people in our community very ill and dieeven in 2024," he said. "Although most will not get seriously ill from COVID, for some people it is like 2020 all over again."
That's particularly true for people who are older, who haven't received their most recent recommended COVID-19 booster, and who haven't taken full advantage of antivirals such as Paxlovid. Chin-Hong noted that only 5% of the COVID-19 patients in the study had been treated with antivirals before they were hospitalized.
Even if the mortality rates for the COVID-19 and flu patients had been equal, COVID-19 would still be the bigger health threat because it is sending more people to the hospital, Al-Aly said.
Between Oct. 1 and the end of March, 75.5 out of every 100,000 Americans had been hospitalized with influenza, according to the Centers for Disease Control and Prevention. During that same period, the hospitalization rate for COVID-19 was 122.9 per 100,000 Americans, the CDC says.
"COVID still carries a higher risk of hospitalization," Al-Aly said. "And among those hospitalized, more will die as a result."
Yet Al-Aly noted with frustration that while 48% of adults in the U.S. received a flu shot this year, only 21% of adults are up to date with their COVID-19 vaccinations, according to the CDC.
Chin-Hong added that more than 95% of adults hospitalized with COVID-19 this past fall and winter had not received the latest booster shot, according to the CDC.
Considering all the tools available to prevent hospitalizations and deathsand especially the fact that they are readily available to patients in the VA systemthe 35% relative risk of death from COVID-19 compared with the flu was "surprisingly high," Chin-Hong said.
And it's not like the flu is a trivial health threat, especially for senior citizens and people who are immunocompromised. It routinely kills tens of thousands of Americans each year, CDC data show.
"Influenza is a consequential infection," Al-Aly said. "Even when COVID becomes equal to the flu, it's still sobering and significant."
The researchers also compared the mortality rates of VA COVID-19 patients before and after Dec. 24, when the omicron subvariant known as JN.1 became the dominant strain in the United States. The difference was not statistically significant.
In just the last two weeks, JN.1 appears to have been overtaken by one of its descendants, a subvariant known as KP.2. It's part of a family of subvariants that's taken on the nickname "FLiRT," a moniker that references some of the mutations that have cropped up on the viruses' spike proteins.
So far, there's no indication that KP.2 is any more dangerous than JN.1, Al-Aly said.
"Are the hospitals filling up? No," he said. "Are ER rooms all over the country flooded with respiratory illness? No." Nor are there worrying changes in the amount of coronavirus detected in wastewater.
"When you look at all these data streams, we're not seeing ominous signs that KP.2 is something the general public should worry about," Al-Aly said.
It's also too early to tell whether KP.2or whatever comes after itwill finally erase the mortality gap between COVID-19 and the flu, he added.
"Maybe when we do a rematch in 2025, that will be the case," he said.
More information: Yan Xie et al, Mortality in Patients Hospitalized for COVID-19 vs Influenza in Fall-Winter 2023-2024, JAMA (2024). DOI: 10.1001/jama.2024.7395
Journal information: Journal of the American Medical Association
2024 Los Angeles Times. Distributed by Tribune Content Agency, LLC.
{{#rendered}} {{/rendered}}
A Chicago nurse has been liberated from her own mind, thanks to a brain-tapping technology called deep TMS.
Gulden, who requested to omit her surname for privacy reasons, worked as a nurse for more than 40 years before COVID-19 rocked the hospital system and took a toll on her mental health.
The mother of four worked at Advocate South Suburban Hospital in Hazel Crest, Illinois, as an ICU and ER nurse.
ARTIFICIAL INTELLIGENCE NOT ALWAYS HELPFUL FOR REDUCING DOCTOR BURNOUT, STUDIES SUGGEST
In an interview with Fox News Digital, Gulden described the "massive chaos" that the 2020 coronavirus pandemic brought to the hospital.
"No matter what we did, it was like a failure," she said. "We were not prepared [for] the onslaught of patients."
Housekeeper Tonia Harvey changes a bed in the Roseland Community Hospital intensive care unit after a COVID-19 patient passed away, April 17, 2020. (E. Jason Wambsgans/Chicago Tribune/Tribune News Service via Getty Images)
"The predictable outcome of coming in through the ER and leaving in a body bag was just devastating."
Despite her many years of medical work, New York City-born Gulden admitted that she "could not cope with it."
By Sept. 2020, she was a "different person," she said.
"I was on autopilot. I lived at work and when I came home, I was not functioning My organization and concentration skills were gone."
NURSES CALL FOR CHANGE AS MANY REVEAL THEY'RE EXTREMELY LIKELY TO LEAVE PROFESSION: EMOTIONAL, STRESSFUL
"It was very, very unlike me, because I'm a single mom. I've raised four kids all by myself but I started to notice that I could not let go of what had transpired during the day."
Gulden told her primary care provider about her symptoms, including "horrible nightmares" that prevented her from sleeping and constant "weeping" that came "from her soul."
Gulden, pictured here, said that working in a hospital during the coronavirus pandemic turned her into a "different person." (Melanie Eilers)
In the span of two years, the doctor prescribed Gulden eight different medications for sleep, PTSD and major depressive disorder, along with cognitive behavior therapy but nothing worked.
Even after the pandemic began to slow down, the nurse described how she hit a "spiral" when she realized COVID-19 created a "chain reaction."
AMERICANS NEED MORE SLEEP, LESS STRESS, EXPERTS SAY, AS GALLUP POLL REVEALS TROUBLING FINDINGS
"[There] was a 51-year-old who had bilateral tumors and needed a mastectomy," she shared. "She'd gone through all her chemo and radiation, and she was ready for her mastectomy, but she had to wait like 11 months."
Added Gulden, "By the time she came back, her tumors had grown back, and that's when I was like, This is never going to be over."
Gulden mentioned that screenings for major health complications were down at least 84% during the pandemic, feeding into a "ripple" of patients who received care too late.
Tamara Jones gives antibiotics to James Davis as he recovers from COVID-19 in the intensive care unit at Roseland Community Hospital on Dec. 16, 2020, in Chicago, Illinois. (Scott Olson/Getty Images)
The nurse said through tears that she decided to leave the hospital and retire, since she "just couldnt function there."
After leaving, she fell into a "hibernation state" of sleeping 16 to 18 hours a day.
"The only reason I got up was to go to the bathroom," she said. "And I'm embarrassed to say I would go weeks without showering."
KETAMINE THERAPY SHOWN EFFECTIVE IN TREATING SEVERE DEPRESSION IN VETERANS, STUDY FINDS
"I lost 54 pounds I got to the point where I couldn't eat, because everything in the refrigerator reminded me of what was on patients trays."
Gulden's "incredibly vivid, horrible nightmares" continued along with other symptoms, including the inability to stay awake. She called it a "complete shutdown."
Gulden received deep TMS treatment at Relief Mental Health in Orland Park, Illinois. (Melanie Eilers)
After Gulden spent three years in "hibernation," a friend introduced her to a new type of mental health treatment called deep TMS (transcranial magnetic stimulation) a magnetized tapping of the brain used to treat various disorders and diseases.
Gulden agreed to visit Dr. Teresa Poprawski, the chief medical officer of Relief Mental Health in Orland Park, Illinois, who helped "put the threads together" on what was triggering her PTSD and other symptoms.
Dr. Aron Tendler, a psychiatrist and chief medical officer of BrainsWay, a brain disorder treatment company, discussed how the therapy works in an interview with Fox News Digital.
Tendler is based in West Palm Beach, Florida and was not involved in Gulden's care. He said the brain is primarily an "electrochemical organ" that sends messages to different parts of the body.
PANDEMIC SKIP, A COVID MENTAL HEALTH PHENOMENON, COULD DELAY MAJOR MILESTONES, EXPERTS SAY
Most symptoms, including depression and anxiety, are controlled by changes in the brain, Tendler said, which can be treated electrically.
Deep TMS is a more "targeted" approach than electroshock therapy, he told Fox News Digital.
Gulden described the sensation of deep TMS as "tapping on specific parts of the brain." (iStock; BrainsWay)
"Transcranial magnetic stimulation uses the principle of electromagnetic induction, where magnetic pulses induce an electrical current inside of neurons," he said.
"Essentially, we are changing the electrical activity in a group of neurons in an area of the brain."
COVID-19 PANDEMIC HAS CAUSED COLLECTIVE TRAUMA AMONG US ADULTS, NEW POLL SAYS
These magnetic pulses only stimulate a specific area of the brain for "a brief period of time," he said, with treatments lasting anywhere from six to 20 minutes. Patients undergo treatments for a series of days, depending on whats necessary.
Tendler described the therapy as a "learning experience" that changes "the state of the brain" through repetitive treatment.
Deep TMS interrupts activity in the brain that is creating unwanted patterns, an expert said. (BrainsWay)
Gulden received deep TMS treatments for five days a week, for six to eight weeks. She described the sensation as "tapping on specific parts of the brain."
After three weeks, she reported a noticeable difference in her cognitive state.
"I realized, Oh my gosh, its been three years since Ive heard the birds," she said. "I see life again. I see my flowers. Before, I couldnt even look at the flowers because they just reminded me of funerals."
PASTOR BASED IN DALLAS SHARES DEPRESSION JOURNEY, URGES OTHERS TO SEEK HELP: DONT HESITATE
Gulden described her quality of life as "just so much better" since receiving treatment.
She still attends cognitive behavioral therapy sessions to hone her coping skills, she said.
"And if I need deep TMS again, I will be back there in a heartbeat," she added.
Deep TMS is covered by "every insurer" across the country, according to one expert. (BrainsWay)
Gulden's goal is to teach others to not feel ashamed about seeking help for their mental health struggles.
"I want people to know that there are interventions," she said.
"The meds did not work for me. Had I not had this treatment today, I don't know where Id be."
Although deep TMS technology was developed in the 1980s, the first treatment application for depression was FDA-cleared in 2009. (BrainsWay)
Most patients experience a 40% to 50% improvement after four weeks of treatment, according to Tendler.
After completing a typical course of 36 treatments, patients have shown 75% to 80% improvement, he said.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
Deep TMS is "not a cure," Tendler said but many patients are able to regain normal function for months or years at a time.
The electrical therapy doesn't have the potential side effects that antidepressants and other treatments can cause, Tendler said, noting that the brain manipulation is "temporary."
"Had I not had this treatment today, I don't know where Id be," Gulden said. (Melanie Eilers)
"I know this might sound like a disadvantage, but it is also an advantage," he said. "We don't do anything to the person's brain that's permanent. We're changing the state of the brain temporarily."
He added, "Generally, we get you out of the state that you were in and then nature takes its course."
Deep TMS can also be paired with other medications, such as antidepressants, Tendler added.
Fox News medical contributor Dr. Marc Siegel cautioned that deep TMS could potentially cause some cognitive and behavioral changes, but called it a "very useful tool" overall. (Dr. Marc Siegel)
Fox News medical contributor Dr. Marc Siegel cautioned that deep TMS could potentially cause some cognitive and behavioral changes, but called it a "very useful tool" overall.
He told Fox News Digital that deep TMS is also "very useful for movement disorders like Parkinson's, with a high rate of success."
"We're changing the state of the brain temporarily."
Siegel cautioned that deep TMS could potentially cause some cognitive and behavioral changes, but called it a "very useful tool" overall.
"[Deep TMS is] still being investigated for various purposes to interrupt aberrant nerve conduction," he said.
CLICK HERE TO GET THE FOX NEWS APP
For other medical professionals suffering from mental health issues, Gulden stressed the importance of having a "healthy health care team," especially following the pandemic.
"I don't care how tough you think you are," she said. "You need to know what the signs are, and you need to know what treatments are available."
For more Health articles, visit foxnews.com.com/health.
COVID-19, which killed 1.1 million Americans and destroyed the lives and livelihoods of millions more, is a man-made virus that escaped from a Chinese lab partly funded by the US government.
Even today, youre not suppose to say that even though its the only plausible scenario.
No, fact checkers will rush in to claim that eminent scientists deny this. Which is because those scientists have too much invested in money, in time, in their own beliefs to admit the truth.
But as Congress continues to probe, that truth is coming out, little by little, and the lies are being exposed:
China tried to deflect blame immediately by saying the virus supposedly began in a wet market of animal meat in Wuhan.
Dr. Anthony Fauci repeatedly argued it evolved in nature and then jumped species in the spring of 2020.
Since then both long investigations and government reports have concluded that the virus is man-made. Fauci grudgingly admitted it could be true.
Anyone who questioned this claim including The Post were censored online in 2020. The reason? A statement published in Lancet by 27 scientists calling it a conspiracy theory.
We now know that statement was drafted by Peter Daszak, president of EcoHealth Alliance, the company working on research in the Wuhan lab. He was just trying to cover his own complicity.
All signs point to a lab leak. The only reason we cant say it conclusively is because China has been allowed to destroy all evidence.
Scientists sometimes experiment with viruses, making them easier to catch or more deadly as a way to determine what might happen or what vaccines may be needed.
But in May 2021, Fauci stated unequivocally that the US has not ever and does not now fund gain-of-function research in the Wuhan Institute of Virology.
On Thursday, NIH Deputy Director Lawrence Tabak directly contradicted that. US taxpayers did fund EcoHealth, which was working on gain-of-function research in Wuhan.
Tabaks new excuse? Gain of function doesnt mean what weve always been told it means. Its perfectly safe, he claimed.
Subscribe to our daily Post Opinion newsletter!
On cue, the National Institute of Health has changed the definition of the term on its website to make it sound benign.
Except it isnt benign. EcoHealth was specifically working in China because such work was not allowed in the United States. What researchers were doing with coronaviruses was very dangerous.
And while there may be a scientific debate about whether such inquiries are worthwhile, deadly viruses have leaked from Chinese labs before. It is the height of irresponsibility for the US to be involved.
The Heritage Foundation has called the coverup of the origins of COVID The Lie of Century. We agree. This is a scandal of colossal scale, one that requires a complete overhaul of the entire National Institutes of Health.
They lied about a weapon that devastated our country. They cant be allowed to get away with it.
The city employee was asked to leave the office 'temporarily' after returning from a trip to Hong Kong during the COVID-19 pandemic.
The City of Richmond did not discriminate against an employee by asking herto leave the office temporarily while awaiting instructions on COVID-19 protocols, according to a B.C. Human Rights Tribunal decision.
Winnie Smrekar, a city employee, had filed a human rights complaintclaiming she was racially discriminated against by her supervisor, Monique Markham, and the city when she tried to return to work following a trip to Hong Kongin 2020.
She claimed she was asked to leave the workplace "because she had the same ethnic origin as those infected by COVID-19 in Wuhan, China," reads thedecision issued on April 25.
The city, on the other hand,denied discrimination and applied to dismiss Smrekar's complaint.
The alleged incident took place on Jan. 28, 2020, one day after Smrekar returnedfrom a trip to Hong Kong, according to the decision.
Markham had met Smrekar in the hallway as she was about to enter the office, asked her how she was feeling, and informed her of concerns about her return to work, according to Smrekar.
"Ms. Smrekar says she told Ms. Markham that she did not visit mainland China, the cases of COVID-19 in Hong Kong were due to travellers arriving from Wuhan, and there was no Health Canada directive to quarantine, nor had she been intercepted at the airport when she returned the day before," wroteB.C. Human Rights Tribunal memberIjeamaka Anikain her decision.
Staff members in the same department, who lived with vulnerable family members,had expressed concern prior to Smrekar's return about working in close proximity with Smrekar due to the spread of COVID-19 from China, according to the decision.
In the days leading up to the incident, the Public Health Agency of Canada had issued a warning for travellers to China; on Jan. 22, Canada implemented a screening protocol for those returning from China.It was unclear whether Hong Kong was included in the advisories.
The first COVID-19 case in B.C. was announced on Jan. 25, 2020.
According to Markham and her manager, they sought direction from occupational health and safety for guidance on health and safety risks and protocols but did not receive a response before Smrekar got back to the office.
As such, Markham's manager advised her to ask Smrekar to leave the office temporarily until she received direction on how to proceed.
Smrekarthen "left the building upset and waited in her car for less than 30 minutes" until Markham told her she could go back in, wrote Anika.
Although Markham apologized to Smrekar the next day and acknowledged the situation "could have been handled better," Smrekar filed a complaint with the city. An external investigator ultimately found Markham didnot breachcity workplace policies.
In the decision, Anikasided with the city and dismissed Smreka's complaint.
She found Smreka did not experience an adverse impact within the meaning of theHuman Rights Codeand her allegation had "no reasonable prospect of success."
The parties did not dispute Smrekar's description of herselfas Chinese by race, colour and ancestry with Hong Kong being her place of origin.
However, in the city's application to dismiss Smrekar's complaint, it argued Smrekar did not experience an adverse impact because she was allowed to return to the office less than 30 minutes after she was asked to leave and it had taken Smrekar's complaint "seriously" and resolved it "effectively."
Anika agreed with the city, stating the "subjective impact" of the incident alone was not enough to prove adverse impact and Smrekar was out of the office for less than 30 minutes.
"Both Ms. Markham and the manager apologized to Ms. Smrekar for the inconvenience and Ms. Smrekar does not allege any further adverse impact either when she returned to the office or anytime afterwards," she wrote.
"On the evidence, the context of the incident could not support the finding of adverse impact that rises to the level of discrimination at a hearing."
While she accepted Smrekarmay have felt "particularly vulnerable" at the time due to personal circumstances, the fact that Smrekar found the incident to be "emotionally upsetting and subjectively stressful" was not enough to show a reasonable prospect she would be able to prove adverse impact during a full hearing.
Got an opinion on this story or any others in Richmond?Send us a letteror email your thoughts or story tips to[emailprotected]. To stay updated on Richmond news, sign up for ourdaily headline newsletter.
If youre looking for an arts and music festival that takes health and community care seriously, look no further than the Mutual Air Festival happening at the Rotunda next Wednesday. The effort is a collaboration between Filter Philly and Philly Breathes, and is a fundraiser for Philly Clean Air Mutual Aid.
Funds from the event will go toward supporting the community with free masks, air filter rentals, and future COVID-safer events.
READ MORE: This is going to hit most people. The COVID state of emergency has ended but the need for support hasnt.
Organizers are asking that all attendees take a COVID-19 test the day of the event and stay home and watch the Instagram livestream if they arent feeling well. And, after they arrive at the festival, they should be prepared to mask up both indoors and outdoors (when not eating, drinking, or taking a COVID test outside). High filtration masks and rapid COVID tests will be available free at the door.
One of our goals is to make this event as accessible as possible not just regarding airborne diseases like COVID.
For those who want to attend but may be overwhelmed by the sights and sounds of a festival, there will be an outdoor chill zone, complete with a low-sensory craft table and livestream of the event going on inside.
The festival will include programming such as a gallery featuring work from visual artist Wit Lpez, a grief space facilitated by Raani Begum, and poetry and music performances. The schedule is as follows:
6 p.m. - 6:50 p.m.: Grief space.
7 p.m. - 8 p.m.: Poetry (Sarena Brown, Liv Zusya Grace, and Uriah aka Gamblin Black Media) and music (Meet the Bug and Ther).
Gallery artists, viewing until 9 p.m.: Wit Lpez and Uriah aka Gamblin Black Media.
Liv Zusya Grace, one of the poets who will be reading on Wednesday and a member of Philly Breathes, hopes that this event will encourage more mask-required shows, poetry readings, gallery showings, and other community events in Philly. As a chronically ill and immunocompromised person, Grace has been deeply affected by COVID.
We are showcasing some amazing artists, musicians, and poets who take COVID precautions. The festival is a place to meet other folks who believe in community care and mutual aid, whether you attend in-person or virtually through our livestream, Grace told The Inquirer by email.
One of our goals is to make this event as accessible as possible not just regarding airborne diseases like COVID, but also regarding fragrance/chemical sensitivities, sensory needs, fat-friendly seating, wheelchair access, and more.
Accessibility accommodations will include:
Required masking
Air purification
Barrier-free entrance, with a ramp toward the back of the building
Accessible, all-gender restrooms
Live captions
And a livestream on Instagram
The idea for the Mutual Air Festival came from a brainstorming session about fundraising initiatives. With both groups having an influx of artists and community facilitators, it was only natural that the event became one that would celebrate these members as well as raise funds to continue supporting the community.
READ MORE: The COVID-19 emergency may be declared over, but resources are still available. Heres where to find help in Philadelphia.
All members of Filter Philly and Philly Breathes are volunteers, and the organizations are non-hierarchical. Philly Breathes operates under the 10 Principles of Disability Justice.
Philly Breathes focuses on distributing masks and is concerned with COVID as well as other environmental issues, such as allergens, pollution, and smoke. Filter Philly currently focuses on lending out air purifiers to create safer spaces and air equity for all.
What were trying to show with putting this festival on is that its not a burden to create COVID-safer spaces, said Selena Yip, a volunteer with Filter Philly. We really want to showcase that its not difficult to require masking. Its not difficult to show community care.
Yip comes from a background of event organizing and, like Grace, is immunocompromised.
I would say that a lot of public spaces are no longer as safe for me to be in, especially community spaces, Yip said.
Its not difficult to show community care.
This particular event is showing that it is possible to create really inclusive and disability justice-centered public spaces and that community care is really important.
Mutual Air Festival will be held at the Rotunda at 4014 Walnut St. in Philadelphia on Wednesday, May 22, starting at 6 p.m. Cost of entry is donation-based and pay-what-you-wish. RSVP at bit.ly/mutualairfest.
COVID-19 cases and deaths internationally have fallen to their lowest levels in four years. The data now permits a comparison between the controversial laissez faire strategy of Sweden and the more restrictive approach of the United States, which emphasized lockdowns, a strategy also adopted by most of Western Europe.
The Swedish tack relied on personal responsibility and voluntary measures rather than government coercion and restrictions. This attitude, ultimately vindicated, was attacked at the time by health officials and the press in Western Europe and North America.
How did America and Sweden fare comparatively?
COVID-19 outcomes were similar. According to the statistics site Worldometer, in terms of officially reported cases since the beginning of the pandemic, Sweden had roughly 27 cases out of 100 people, the U.S. had 34 cases out of 100. This was only reported cases, and the best estimate is that considering all cases, whether reported or not, both countries had between 80 and 90 cases per 100, so the difference in infection rates disappears. Neither a lockdown-intensive nor a permissive strategy minimized the ultimate number of COVID-19 cases.
The numbers once again lean slightly toward Sweden, but it is likely the health of Swedish citizens versus that of the U.S. was responsible, instead of the superiority of the Swedish strategy. In the U.S. overall, there were 3.7 COVID-19 deaths per 1,000 people; in Sweden, 2.7 COVID-19 deaths per 1,000. Based on this, no one can claim the U.S. did better than Sweden, but it is not a ringing endorsement of the Swedish approach. Neither country protected high-mortality nursing home patients, especially early in the pandemic. Many countries, including their Scandinavian neighbors, had fewer COVID-19 deaths per population than Sweden. Norway, Denmark and Finland all quickly closed their national borders; Finland erected internal borders.
The lesson is that COVID-19 cases and outcomes are probably not primarily determined by national strategy. After four years, no major country avoided high COVID-19 infection rates. While approaches to protect high-risk patients may limit morbidity and mortality at the margins, COVID-19 deaths are related more to national health, age and demographic breakdown, and population immunity. Assessing lockdown strategies by measuring COVID-19 cases and deaths is fraught with error; counterexamples abound.
Public health experts use the term excess deaths to describe deaths from all causes in a given interval when comparing with the number of expected deaths based on historic patterns. From 2020 to 2023, excess deaths were elevated in every developed country but were up only 5% in Sweden compared with between 10% and 15% in the U.S. The 5% figure is the lowest figure in any industrialized Western country, including the Scandinavian countries with lower COVID-19 mortality. Many excess U.S. deaths can be attributed to lockdowns and include deaths of despair suicides, drug overdoses and alcoholism and deaths resulting from delayed health care. Sweden almost certainly avoided many of the deaths associated with lockdowns in the U.S.
The economic figures during the pandemic tell a similar story. According to the Organization for Economic Co operation and Development, the U.S. economy, although fairly resilient, shrank by 1.2% after 2021 against what was forecast. (The Eurozones fell by 2.1%.) The Swedish economy grew by 0.4% against what was forecast. Inflationary pressures post-pandemic are not as severe in Sweden as in the U.S., where the government employed a greater, potentially inflationary fiscal stimulus.
The most important outcome difference between the U.S. and Sweden was in childrens education. Prolonged U.S. school closures caused educational damage to students not seen in Sweden. Beginning in March 2020, public schools in the U.S. closed, sending 50 million students home. Some private and religious schools, as well as some schools in Florida, opened up in the second half of 2020, but as many as half of all American public school students stayed out of school until the second half of 2021.
Several researchers from American universities found that by the spring of 2022, the average U.S. student lagged by approximately one-half year in math and one-third of a year in reading.
The Public Health Agency of Sweden recommended that secondary schools and universities switch to remote education for the final three months of the 2020 spring term, but schools opened in autumn. There was another two-month in-school hiatus in December 2020 and January 2021 during a variant outbreak, but almost all preschools and elementary schools remained open. Swedish researchers concluded there was no evidence of a learning loss in early reading skills in Swedish primary school students, and the decision to keep schools open benefited Swedish primary school students.
Taking into account all aspects of the pandemic excess deaths, economic health and childrens education the long view suggests that while not ideal, the Swedish strategy was superior. The coronavirus was so contagious and mutated so quickly that tight lockdowns were unsuccessful in controlling spread. And the longer the lockdowns, the greater harm to the populace from factors other than COVID-19.
The effectiveness of lockdowns during COVID-19 is an important question, scientifically and historically but not a definitive blueprint for the future. The next contagion may spread differently and require different measures.
The most important takeaway from the Swedish COVID-19 experience is not that Sweden controlled COVID-19 better, but that any national strategy must account for the effects on the countrys economic, social, educational and mental health.
Dr. Cory Franklin is a retired intensive care physician and co-author of the new book The COVID Diaries 2020-2024: Anatomy of a Contagion As It Happened. He wrote this column for the Chicago Tribune.
